ACP-211 vs AV-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ACP-211
Developed by Acadia Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07284667 (registry estimate)
No aligned efficacy figure on record for this race.
AV-101
Developed by VistaGen Therapeutics
NCT02484456 · Phase 2 · completed
Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).
Reported efficacy
Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 1); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 2); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 3); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 7); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 13): Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) (missed)
Result source: NCT02484456
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ACP-211 | AV-101 |
|---|---|---|
| MADRS, change (acute) | —Not reported | 29.7 vs 27.1+2.6 vs placeboNCT024844565 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- ACP-211
- —Not reported
- AV-101
- 29.7 vs 27.1+2.6 vs placeboNCT02484456
5 other results
- 30.4 vs 28.6 NCT02484456
- 29.9 vs 30.8 NCT02484456
- 29.5 vs 29.8 NCT02484456
- 28.8 vs 28.8 NCT02484456
- 29.3 vs 29.5 NCT02484456
CGI-S, change (acute)
- ACP-211
- —Not reported
- AV-101
- —Not reported
MADRS response
- ACP-211
- —Not reported
- AV-101
- —Not reported
MADRS remission
- ACP-211
- —Not reported
- AV-101
- —Not reported
Relapse (% of patients)
- ACP-211
- —Not reported
- AV-101
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ACP-211: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ACP-211: 0 of 4 rows · AV-101: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | AV-101 |
|---|---|
| Dropout rate | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
| Serious AEs | 5.3%1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result5.3%1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | 1,080 mg for 1 Week headache 26.3% (placebo 15.8%) insomnia 15.8% (placebo 10.5%) musculoskeletal pain 15.8% (placebo 15.8%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result1,440 mg for 1 Week abdominal discomfort 5.3% (placebo 10.5%) asthenia 5.3% (placebo 0%) cold sweat 5.3% (placebo 0%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
AV-101
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · AV-101's landscape